CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Nevakar

Nevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.

Ascend Therapeutics

Ascend Therapeutics is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TMS International

TMSi is specialized in developing of high-quality measurement systems for electrophysiological parameters such as EEG and High Density EMG. Our systems are highly versatile and have the best data quality possible.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.

Alpha Genesis

Alpha Genesis is a Yemassee, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.